Vaccine formulation

US6890540B1 · kind B1 · utility

Assignee

• Eurocine AB · SE

Inventors

• Ulf Schroder · Sundbyberg, SE
• Stefan Svenson · Stuvsta-Snättringe, SE

Key dates

• Filing date: Feb 9, 2000
• Grant date: May 10, 2005
• Expiry date: Aug 5, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/6037
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A vaccine formulation against a microorganism is disclosed. The formulation comprises: as adjuvant, one or more substances selected from a) monoglyceride preparations having at least 80% monoglyceride content and b) fatty acids of the general formula CH3—(CH2)n—COOH where “n” may be varied between 4 and 22, and where the acyl chain may contain one or more unsaturated bonds, and as immunizing component, an immunogenic product consisting of antigenically active carbohydrate moieties (ACM) derived from said microorganism which are each covalently coupled, possibly via identical divalent bridge groups, to immunologically active carriers (IAC). The vaccine formulation is e.g. against Mycobacterium tuberculosis and in that case the formulation may comprise, as adjuvant, a mixture of mono-olein and oleic acid, and possibly soybean oil, and, as immunizing component, lipoarabinomamman-tetanus toxoid (LAM-TT).